NCT05633979View on ClinicalTrials.gov

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2032

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab deruxtecan

Given by IV (vein)

DRUG

Valemetostat

Given by PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Daiichi Sankyo
All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05633979 - Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter